OBJECTIVES: Surveillance after resection of solitary fibrous tumours of the pleura (SFTP) remains undefined. This study reviews our experience with surgical treatment of SFTP to determine the specific risk factors to predict recurrence.
INTRODUCTION
Solitary fibrous tumours of the pleura (SFTP) are infrequent neoplasms of mesenchymal origin that are thought to arise from submesothelial connective tissue [1] . In most cases, these tumours have a benign biological behaviour, where primary surgical resection remains the mainstay of curative treatment. However, there is a subpopulation of patients who develop pleural recurrence, or even more rarely, metastasize and die. Factors associated with a malignant phenotype have been recognized for years, based on a 1989 landmark Armed Forces Institute of Pathology study by England et al. [2] . In 223 SFTPs, factors associated with aggressive behavior included origin from the parietal pleura, absence of a stalk, size >10 cm, presence of hypercellularity, pleomorphism, tumour necrosis or haemorrhage and ≥4 mitosis/10 high-power fields (HPFs).
Despite recognition in the early 1990s of histopathological risk factors for predicting malignant behaviour of resected SFTP, more contemporary surgical series [3] [4] [5] [6] [7] [8] [9] [10] have combined clinical and morphological criteria to classify tumours as 'malignant', making comparisons across few studies difficult. Furthermore, no study, to date, has defined radiographical follow-up and surveillance after complete resection. In the absence of consensus regarding optimal postoperative surveillance for recurrence (in both benign and malignant phenotypes), various radiographical studies and follow-up intervals are observed after resection despite benign behaviour in most cases [11] .
The objective of the present study is to review our experience with the surgical treatment of SFTP and tumour recurrence. We evaluate the ordered use of clinical and pathological features associated with recurrence by proposing a predictive scoring system. The proposed scoring system aims to classify the patients according to their risk of recurrence to inform postoperative surveillance. A reliable scoring system potentially reduces unnecessary radiation exposure from imaging studies and relaxes observation protocol in patients at low risk of recurrence while reserving a stricter follow-up protocol among patients at high risk.
MATERIALS AND METHODS
The study population included consecutive patients undergoing surgical treatment for SFTP at the Massachusetts General Hospital between 1st January 1977 and 31st December 2010. Patients were identified in a prospectively organized pathology and surgery database, and retrospectively analysed. Demographics, preoperative, intraoperative and postoperative data as well as long-term outcome were recorded. The Institutional Review Board approved this retrospective chart review, including subject selection and confidentiality, and waived the need for patient consent; they also granted permission to contact patients by telephone when feasible.
All patients underwent diagnostic chest computed tomography and occasionally, magnetic resonance imaging (MRI). Tissue to confirm a diagnosis was obtained before resection in 39% of patients. Available histological slides were reviewed by a single pulmonary pathologist (M.M.K.) to determine the factors known to be associated with recurrence and/or malignant behaviour [2] . The presence of hypercellularity, pleomorphism and nuclear atypia, necrosis or haemorrhage and the mitotic index (the number of mitotic figures per 10 HPFs) were recorded. Histological slides available for 38 of the 59 (64%) patients were individually stained for a Ki67 proliferation index. Immunostaining of CD34, pan-cytokeratin and vimentin was not routinely performed for SFTP until 1998 at our institution.
Long-term follow-up data were obtained primarily from the patient's medical record. Where feasible, patients were contacted about their disease and follow-up visits, specifically about the results of the last imaging study of the chest. The Social Security Death Index (SSDI) was consulted to determine the vital status of the patients. The primary endpoint of this study is tumour recurrence. Secondary endpoints analysed were postoperative morbidity, in-hospital or 30-day mortality and overall and diseasefree survival.
Statistical analysis
Data were recorded in a database designed in Microsoft Office Excel 2007 (Microsoft, Redmond, WA, USA) and later exported to Stata/SE 10.1 statistical software (StataCorp LP, College Station, TX, USA). Variables were analysed as proportions, means or medians according to their nature. Overall survival was defined as the time from surgery to death from any cause based on SSDI data. Disease-free survival was defined as the time from surgery to tumour recurrence or to death from any cause based on data from medical records only. Recurrence was defined as the time from surgery to the date of first evidence of tumour recurrence, censoring patients who died without experiencing recurrence based on medical records. Potential risk factors for recurrence were analysed by the Kaplan-Meier and Cox proportional hazard methods. A multivariate model including six morphological and histopathological variables was elaborated based on univariate analysis results and literature findings. Harrell's C-statistic was calculated to assess the predictive power, and its 95% confidence interval (CI) was calculated by bootstrapping with 1000 repetitions. A predictive scoring system was constructed with variables included in this model in order to predict recurrence. Receiver operating characteristic (ROC) curves were plotted for the scoring system and were compared with ROC curves constructed from previously described criteria for malignancy of SFTP, namely England et al.'s criteria [2] (the presence of hypercellularity, pleomorphism/atypia, necrosis/haemorrhage or a mitotic count ≥4 mitosis/10 HPFs) and de Perrot's classification [11] (England's criteria plus the presence of stalk). For all comparisons, statistical significance was considered with P-value of <0.05.
RESULTS
Fifty-nine patients underwent surgical treatment of primary SFTP during the study period. Baseline characteristics and presenting symptoms are described in Table 1 . Tumours were located in the right chest in 30 (51%) patients. At least 6 (10%) patients harboured an associated pleural effusion. Preoperative tumour diagnosis was obtained in 23 (39%) patients; 17 (29%) of these underwent fine-needle aspiration (FNA) biopsy, 4 (7%) had a core needle biopsy and 2 (3%) open incisional biopsy. Percutaneous needle biopsies were often unsuccessful: a preoperative diagnosis was reached in only 6 of all 21 patients (29%), and specifically in only 3 of 17 (18%) FNA and 3 of 4 (75%) core needle biopsies.
This study includes different surgical approaches. Thoracotomy was preferred in 41 (69%) patients, followed by video assisted thoracoscopic surgery in 14 (24%), of whom 3 required conversion to thoracotomy. Median sternotomy and a thoracoabdominal incision were used in 2 (3%) patients each. A complete (R0) resection was performed in all patients. Wedge resection of the lung was required in 43 (73%) cases, lobectomy in 4 (7%) and bilobectomy and segmentectomy in 1 (2%) each; en bloc chest wall resections were required in 5 (8%) cases.
Postoperative course
All patients had a chest tube placed at the end of surgery. The median duration of chest drainage was 3 days (range 1-15 days). Seven (12%) patients experienced postoperative complications: 4 (7%) had atelectasis while haematuria, pulmonary oedema and postoperative bleeding requiring re-exploration occurred in 1 (2%) each. No patients died in-hospital or within 30 days after surgery.
Tumour characteristics and histopathology
SFTP originated from the visceral pleura in 40 (68%) cases and the parietal pleura in 16 (27%), and were intrapulmonary in 3 (5%). Tumours originated from the left upper lobe in 8 (14%) patients, the left lower lobe in 14 (24%), the right upper lobe in 8 (14%), the right middle lobe in 1 (2%), the right lower lobe in 11 (19%), the chest wall in 9 (16%), the mediastinum in 5 (9%) and the diaphragm in 2 (3%). A stalk was observed in 38 (67%) cases. The median tumour size in the long axis was 5 (range 0.7-33 cm); 14 (25%) patients had SFTPs larger than 10 cm.
Histopathological review identified hypercellularity in 14 (24%) cases, pleomorphism or atypia in 8 (14%), necrosis or haemorrhage in 6 (10%), and the median number of mitosis per 10 HPFs was 1 (range 0-12), with only 4 patients having ≥4 mitosis/ 10 HPFs. Ki67 staining of 38 tumour specimens showed a median proliferative index of 5.2% (range 0.5-13.5%); seven (18%) tumours had a Ki67 of ≥10%.
Long-term follow-up and overall survival
No patient received adjuvant therapy after surgical resection. Cohort median overall survival was 24 years after a median follow-up of 12.9 years (range 1 month-32.8 years (Fig. 1C ). There were no differences in overall survival when comparing patients classified as high or low risk based on the proposed scoring system for recurrence (P = 0.218), by England's criteria (P = 0.107) or de Perrot's classification (P = 0.314).
Risk factor analysis for recurrence: development of a scoring system
After a median follow-up of 8 years (range 1 month-27 years), there have been 8 (14%) recurrences. Median cohort recurrence has not been achieved. Median time to recurrence was 6 years (range 2-16 years), and the latest recurrence observed was 16 years after resection. All recurrences were ipsilateral to the original tumour without extrathoracic disease. Two patients required chest wall resection to achieve an R0 resection. On univariate analysis, the greatest impact on survival was observed for tumour size, presence of a pleural effusion, hypercellularity, necrosis and ≥4 mitosis/HPFs. Symptoms at presentation, sessile morphology and pleomorphism were not significant for recurrence among the parameters listed in Table 2 . Factors found to be most associated with recurrence-free survival of SFTP are shown in Fig. 2 . A multivariate model was constructed with six morphological and histopathological parameters that harboured P < 0.100 (i.e. pleural origin, presence of stalk, size, hypercellularity, presence of necrosis and mitotic count). Pleural effusion was omitted from the scoring system due to the low frequency rate in our series and the lack of accurate description of this finding in the reviewed medical records. Harrell's C-statistic was calculated for this model, being 0.953 (95% CI 0.909-0.997). The single variable significant on multivariate analysis was tumour size ≥10 cm. A scoring system was constructed assigning one point to each of the six tumour characteristics, as shown in Table 3 . The median score in our cohort was 1 (range 0-5). Scores had the following distribution: 0 in 25 (42%) patients, 1 in 11 (19%), 2 in 11 (19%), 3 in 7 (12%), 4 in 3 (5%), 5 in 2 (3%) and 6 points in no patients. ROC curves were plotted for this scoring system as shown in Fig. 3 and compared with previously established criteria for malignancy. The area under the ROC curve was 0.966 (0.924-1.000). The scoring system was most predictive for tumour recurrence when using a score of three points or greater as cut-off, yielding a sensitivity of 100%, specificity of 92%, a positive likelihood ratio of 12.5 and a negative likelihood ratio of <0.0001. The proposed scoring system's area under the ROC curve was significantly greater than that obtained with England Accordingly, 12 (20%) patients were then classified at high risk for recurrence (≥3 points), while the remaining 47 (80%) were classified at low risk (<3 points). The contribution of clinical and histopathological parameters to the patient score is listed in Table 4 . Patients with scores ≥3 often underwent more aggressive surgery (i.e. lobectomy or chest wall resection). SFTP recurrence among groups was significantly lower in patients classified as low risk: 0% at 15 years compared with 77% in patients considered at high risk (P < 0.0001) as shown in Fig. 4 . No recurrences occurred in the group classified as low risk (<3 points). Tumour recurrences were ipsilateral to the previously resected tumour in all cases. A solitary recurrent lesion was found in 4 patients, while multiple lesions were observed in 4. Four recurrent cases were seen to arise from the parietal pleura, while in the other 4 it was found to be invading both the visceral and parietal pleura. No recurrent tumour was pedunculated. In 1 case, a solitary recurrent tumour was observed to have a benign histology without mitotic activity; among the other seven recurrent tumours, the mitotic count ranged from 1 mitosis to 17 mitosis/HPFs with five tumours having a mitotic count greater than 4/HPF.
DISCUSSION
Solitary fibrous tumours are rare pleural neoplasms with benign histopathology in 80% of cases. Despite benign characteristics, some of these tumours have the propensity to recur via malignant transformation-likely through an undefined molecular pathway of tumourigenesis. A few studies have attempted to crystallize features that portend malignant behaviour and recurrence. Early reports focused on histopathological characteristics (such as necrosis, mitosis, hypercellularity and pleomorphism) The numbers in bold represent a P-value that are statistically significant. [2] . Later, p53 expression [5] , sessile tumour morphology (inverted tumours) [11] and patient symptoms [3] were correlated with malignant potential. While no single factor has been elucidated to help predict the biological behaviour of SFTP, we found that tumour size alone was a sole predictor (hazard ratio, HR = 11.1) of recurrence-free survival on multivariate analysis of all clinical and pathological criteria. Molecular studies [5, 12] have contributed to the differentiation of localized fibrous tumours from malignant mesothelioma, but still fall short in predicting recurrence. Localized tumours typically lack the expression of cytokeratin, but can express vimentin (a mesenchymal marker), CD34 (a haematopoietic stem cell marker) and CD99 (a spindle cell tumour marker) [12, 13] . The expression of Bcl-2 (an apoptosis regulator and proto-oncogene) can be useful in CD34-negative tumours to confirm SFTP [11, 14] . In a study that included the examination of several actionable mutations (among them c-kit, BRAF, platletderived growth factor receptor, c-met and epidermal growth factor receptor) in 88 patients diagnosed with SFTP, only high expression of p53 and tumour necrosis were observed to influence disease-free survival [5] . Of 14 resected tumours evaluated for CD34 in our case series, CD34 expression was positive in all Similar to previous published series, we did not routinely perform immunohistochemistry on all cases. The immunohistochemical characterization of SFTP is not standardized across institutions: in the current era, a consensus of opinion should be organized to unify criteria and make comparisons feasible among future publications on SFTP.
Given the slowly progressive and sometimes unpredictable biological nature of SFTP, a challenging issue in these patients is appropriate surveillance. Recurrence after complete resection is infrequent in the majority of patients. Single-institution case series report recurrence in 10-15% of resected tumours [3] [4] [5] [6] [7] 10] . We observed recurrence in 14% of our study cohort with 37.5% (3 of 8) of the cases having a histologically 'bland' or benign pathology. Moreover, our median time to recurrence of 6 years and latest recurrence at 16 years were long. The proposed scoring system as applied to our patients enabled us to identify patients without recurrence in more than 20 years (score <3). Since there is increasing concern about cumulative radiation exposure and cost from surveillance imaging [15] , we recommend that patients with the lowest risk of recurrence undergo a less-aggressive surveillance imaging strategy.
After reviewing the literature for SFTP, the use of diagnostic FNA biopsy has a disappointing yield from 20 to 39%. We and others have found improved yields and better tumour characterization with the use of a core needle biopsy. Diagnostic biopsy of these lesions may not always be necessary, but 75% of the core samples were diagnostic in our study. We also found that preoperative percutaneous embolization of feeding arteries in large tumours (>20 cm) can contribute to reduced intraoperative blood loss. The use of a thoracoabdominal approach to SFTP was very helpful to extricate large tumours.
Our specific goal was to develop a reliable prediction of recurrence to influence the use of surveillance chest imaging. The standard imaging is still chest computed tomography, but chest MRI is a non-radiation alternative with improving visualization. Based on our risk classification, 12 patients in our study cohort would require a strict follow-up with chest imaging, while 20 based on England et al. criteria, and 30 based on de Perrot's classification would require this kind of surveillance (even though de Perrot et al. [11] recommend at least yearly radiological examination for all patients). Our proposed score and classification are simple and easy to implement in clinical practise. Additionally, this scoring system could standardize future literature on SFTP, thus allowing direct comparisons or pooling of data. Nevertheless, this model must be validated and refined in other patient populations of resected SFTP. Our study has obvious limitations by virtue of a small sample size and the retrospective nature of data collection. The analysis could be strengthened using more current immunohistochemical interrogation of all tumours. As decades have elapsed since this study, paraffin sections of some older tumours were unavailable. The proposed scoring system for SFTP recurrence will clearly need further validation in larger and different populations; specifically, the proposed simple scoring system (assigning one point to each variable, some of which were not significant on multivariate analysis, but were included because of the consistent association reported in the literature) needs to be enhanced by performing comparisons with a weighted score based on the multivariate recurrence-free survival model coefficients derived from larger samples. There is also the question of defining an intermediate-risk group, which can only be achieved by combining single-centre populations. Interestingly, the role of Ki67 staining seems promising as a predictive variable for tumour recurrence. Seven of the eight recurrences had Ki67 ≥10%. We were unable to include this variable in our multivariate model for recurrence due to the small number of slides available to perform this staining.
CONCLUSIONS
Surgical treatment of SFTP remains the primary curative therapy with low perioperative morbidity and mortality. A new scoring system constructed on common clinical and histological characteristics is easy to compute, correlates well with recurrence and predicted all recurrences when retrospectively applied to our study cohort. The score may be used to assess prognosis and to guide postoperative surveillance. If validated in a larger population, selected patients with excellent prognosis may not require surveillance imaging. In contrast, patients with scores predictive of disease recurrence may be selected for the study of adjuvant therapy and frequent surveillance imaging.
